NCT05517486View on ClinicalTrials.gov

Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

August 21, 2022

Study Completion Date

May 3, 2023

Conditions
Postherpetic Neuralgia
Interventions
DRUG

GTX-101

Bupivacaine HCl metered spray

DRUG

Bupivacaine HCl subcutaneous injection

Bupivacaine HCl, 50 mg/10 mL

Trial Locations (1)

Unknown

Clinical Research Unit, Montreal

Sponsors
All Listed Sponsors
lead

Grace Therapeutics Inc.

INDUSTRY